Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Ready to finally stop fighting
Tirzepatide, a dual GLP-1 / glucose-dependent insulinotropic polypeptide (GIP) agonist, was superior to semaglutide in reducing HbA 1c and body weight in the SURPASS-2 trial, a phase 3, randomised, open-label trial comparing the efficacy and safety of tirzepatide vs semaglutide once weekly as add-on therapy to metformin in individuals with type 2 diabetes [10]
Its cyclic structure formed via a lactam bridge between lysine and aspartate residues confers substantially greater metabolic stability than native -MSH and the linear Melanotan 1 analogue, and produces a distinct, broad-spectrum receptor activity profile
There is no way of knowing how much of the peptide is in there, whether the contents are sterile or whether there are other contaminants or toxins in there that you risk administering to yourself. Not knowing what is in the vial
Email [email protected] Healthcare Technology Thought Leadership from Nelson Advisors Market Insights, Analysis & Predictions
US$ 27.24
US$ 21.31
US$ 29.48
US$ 24.75
US$ 23.19
US$ 21.52
US$ 26.14
US$ 29.21
US$ 22.70
